Aura Biosciences, Inc. (AURA)

NASDAQ • Healthcare

$6.3

-$0.16 (-2.5%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$6.33

Previous Close$6.3

Day Range$6.16 - $6.4

Avg. Volume (3M)921.1K

Market Cap$653.3M

52 Week Range

$4.73$9.54

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$131M

EPS (TTM)

-$1.78

ROA (TTM)

-37.63%

Current Ratio

16.82

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+4.1%Q3 2025-$0.47

+13.0%Q4 2025-$0.4

+14.0%Q1 2026-$0.37

-25.0%Q2 2026-$0.5

-28.0%Q3 2026-$0.48

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -28.0%

Aura Biosciences’ second fiscal quarter of 2026 earnings trailed consensus, with EPS of -$0.48 versus an estimate of -$0.38 (difference -$0.10), based on preliminary results reported August 11, 2026. The company posted GAAP net income of roughly -$45.6 million, down -68.9% year over year from about -$27.0 million, alongside an operating loss of about -$48.1 million as it continued investing in its oncology development work, including the AU-011 program. The reported EPS compared with -$0.47 a year ago (eps_actual YoY -2.1%). Cash flow remained negative, with operating cash flow of roughly -$31.8 million, and the company repurchased about $39.1 million of stock during the period. Next-period consensus calls for EPS of -$0.37.

Next report — what to expect

Aura Biosciences, Inc. (AURA) is set to report on November 12, 2026. Wall Street is looking for consensus EPS of -$0.368. The company has beaten EPS in 4 of 8 most recent quarters, so traders may focus on whether results align with that pattern and on any update that clarifies revenue timing.

View full earnings history

About Aura Biosciences, Inc.

Aura Biosciences, Inc. is a NASDAQ-listed biotechnology company in the healthcare sector that develops cancer treatments. It is a small-cap drug developer centered on ocular and urologic oncology, with its lead program AU-011 in development for primary choroidal melanoma and built on a proprietary virus-like drug conjugate platform.

Name

Aura Biosciences, Inc.

CEO

Natalie C. Holles

Website

www.aurabiosciences.com

Industry

Healthcare

Year Founded

2009

Employees

113

Today's Snapshot

AI-generated

AURA closed 2.5% lower at 6.30, in line with a weaker sector. AURA reports earnings on 5 November.

Trading Volume

Below 10d avg (898.2K)

721.8K

vs S&P 500 Today

Underperforming Market

-1.96%

Updated: October 23, 2026 at 20:15 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

AURA, trading at 6.30, shows technical weakness consistent with a sell rating. Momentum indicators are muted with RSI in the mid-40s and a slight negative momentum reading, while the price sits below most short- and long-term moving averages and below the classic pivot, suggesting resistance overhead. ADX is low, indicating the trend lacks strength, yet on-balance volume is clearly negative, signaling distribution. Volatility is moderate with an ATR near 0.30 (about 4.8%), which has not reversed the selling bias. Technical takeaway: weak price position and negative volume support a sell bias.

All signals

EMA (5 indicators)$6.36 - $6.79
Sell
RSI (14)45.66
Neutral
Stochastic %K (14, 3, 3)49.69
Neutral
MACD Level (12, 26)-0.09
Neutral

Peers & Related Assets

IMNMImmunome, Inc.

$17.99-1.5%

AKTSAktis Oncology, Inc.

$15.73-6.2%

EYPTEyePoint Pharmaceuticals, Inc.

$0.4-5.5%

OCSOculis Holding AG

OCGNOcugen, Inc.

BCYCBicycle Therapeutics plc

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.